Prognostic implications of systemic immune-inflammation index in patients with bone metastases from hepatocellular carcinoma treated with radiotherapy

Background Previous studies have shown that systemic inflammation indicators could predict the survival outcomes of patients with malignant tumors receiving various treatments. Radiotherapy, as a crucial treatment modality, effectively alleviates discomfort in patients with bone metastasis (BM) and greatly improves the quality of life for them. This study aimed to investigate the prognostic value of systemic inflammation index in hepatocellular carcinoma (HCC) patients with BM treated with radiotherapy. Methods We retrospectively analyzed clinical data collected from HCC patients with BM who received radiotherapy in our institution between January 2017 and December 2021. The pre-treatment neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and systemic immune-inflammation index (SII) were derived to determine their relationship with overall survival (OS) and progression-free survival (PFS), using the Kaplan-Meier survival curves. The optimal cut-off value of the systemic inflammation indicators for predicting prognosis was assessed by receiver operating characteristic (ROC) curves. Univariate and multivariate analyses were performed to ultimately evaluate the factors associated with survival. Results The study included 239 patients with a median 14-month follow-up. The median OS was 18 months (95% confidence interval [CI] = 12.0-24.0) and the median PFS was 8.5 months (95% CI = 6.5-9.5). The optimal cut-off values for the patients were determined by ROC curve analysis as follows: SII =395.05, NLR=5.43 and PLR = 108.23. The area under the receiver operating characteristic curve values for SII, NLR and PLR in disease control prediction were 0.750, 0.665 and 0.676, respectively. Elevated systemic immune-inflammation index (SII>395.05) and higher NLR (NLR>5.43) were independently associated with poor OS and PFS. In multivariate analysis, Child-Pugh class (P = 0.038), intrahepatic tumor controlled (P = 0.019), SII (P = 0.001) and NLR (P = 0.007) were independent prognostic factors of OS and Child-Pugh class (P = 0.042), SII (P < 0.001) and NLR (P = 0.002) were independently correlated with PFS. Conclusion NLR and SII were associated with poor prognosis in HCC patients with BM receiving radiotherapy and might be considered reliable and independent prognostic biomarkers for HCC patients with BM.

[1]  Haiyong Wang,et al.  Pre-radiotherapy systemic immune inflammation index associated with overall survival in patients with advanced EGFR mutant non-small cell lung cancer receiving thoracic radiotherapy , 2022, Clinical and Translational Oncology.

[2]  Shulan Sun,et al.  Predictive value of NLR and PLR in response to preoperative chemotherapy and prognosis in locally advanced gastric cancer , 2022, Frontiers in Oncology.

[3]  P. Lequerica-Fernández,et al.  Prognostic implications of preoperative systemic inflammatory markers in oral squamous cell carcinoma, and correlations with the local immune tumor microenvironment , 2022, Frontiers in Immunology.

[4]  Huifang Liang,et al.  Bone metastasis of hepatocellular carcinoma: facts and hopes from clinical and translational perspectives , 2022, Frontiers of Medicine.

[5]  M. Mego,et al.  Inflammatory Indexes as Prognostic Factors of Survival in Geriatric Patients with Hepatocellular Carcinoma: A Case Control Study of Eight Slovak Centers , 2022, Journal of clinical medicine.

[6]  K. Sartorius,et al.  Emerging Perspectives of Bone Metastasis in Hepatocellular Carcinoma , 2022, Frontiers in Oncology.

[7]  J. Menten,et al.  ESTRO ACROP guidelines for external beam radiotherapy of patients with complicated bone metastases. , 2022, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[8]  T. Rygiel,et al.  Tumor Microenvironment of Hepatocellular Carcinoma: Challenges and Opportunities for New Treatment Options , 2022, International journal of molecular sciences.

[9]  J. Arnoletti,et al.  Pancreatic Ductal Adenocarcinoma (PDAC) circulating tumor cells influence myeloid cell differentiation to support their survival and immunoresistance in portal vein circulation , 2022, PloS one.

[10]  M. Braga,et al.  Association Between Systemic Inflammation and Malnutrition With Survival in Patients With Cancer Sarcopenia—A Prospective Multicenter Study , 2022, Frontiers in Nutrition.

[11]  Jing Chen,et al.  Preoperative Prognostic Nutritional Index and Neutrophil-to-Lymphocyte Ratio Predict Survival Outcomes of Patients With Hepatocellular Carcinoma After Curative Resection , 2022, Frontiers in Oncology.

[12]  Liaoliao Dong,et al.  Neutrophils in cancer carcinogenesis and metastasis , 2021, Journal of Hematology & Oncology.

[13]  Hong Chang,et al.  Prognostic significance of preoperative systemic inflammatory biomarkers in patients with hepatocellular carcinoma after microwave ablation and establishment of a nomogram , 2021, Scientific Reports.

[14]  K. Dou,et al.  Prognostic value of preoperative inflammatory markers in patients with hepatocellular carcinoma who underwent curative resection , 2021, Cancer Cell International.

[15]  Xutong Li,et al.  Prognostic significance of inflammation-based score in patients with hepatocellular carcinoma after liver transplantation , 2021, European journal of gastroenterology & hepatology.

[16]  Peng Du,et al.  Diagnostic Value of Inflammatory Factors in Pathology of Bladder Cancer Patients , 2020, Frontiers in Molecular Biosciences.

[17]  M. Cho,et al.  Systemic immune-inflammation index predicts prognosis of sequential therapy with sorafenib and regorafenib in hepatocellular carcinoma , 2020, BMC cancer.

[18]  Chengliang Zhao,et al.  Diagnostic and prognostic nomograms for bone metastasis in hepatocellular carcinoma , 2020, BMC Cancer.

[19]  Hongyu Wang,et al.  Dynamic Changes in the Neutrophil-to-Lymphocyte Ratio Predict the Prognosis of Patients with Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization , 2020, Cancer management and research.

[20]  Y. Huang,et al.  Prognostic impact of elevated pre-treatment systemic immune-inflammation index (SII) in hepatocellular carcinoma , 2020, Medicine.

[21]  Xiao-mei Zhao,et al.  Pre/Post-Treatment Dynamic of Inflammatory Markers Has Prognostic Value in Patients with Small Hepatocellular Carcinoma Managed by Stereotactic Body Radiation Therapy , 2019, Cancer management and research.

[22]  M. Lotze,et al.  Prognostic Value of the Systemic Immune-Inflammation Index (SII) After Neoadjuvant Therapy for Patients with Resected Pancreatic Cancer , 2019, Annals of Surgical Oncology.

[23]  Li Ma,et al.  A predictive model for treatment response in patients with locally advanced esophageal squamous cell carcinoma after concurrent chemoradiotherapy: based on SUVmean and NLR , 2019, BMC Cancer.

[24]  Tingting Li,et al.  Preoperative systemic inflammation score (SIS) is superior to neutrophil to lymphocyte ratio (NLR) as a predicting indicator in patients with esophageal squamous cell carcinoma , 2019, BMC Cancer.

[25]  I. B. Manuaba,et al.  Pretreatment Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-to-Lymphocyte Ratio (PLR) as a Predictive Value of Hematological Markers in Cervical Cancer , 2019, Asian Pacific journal of cancer prevention : APJCP.

[26]  M. Schlesinger Role of platelets and platelet receptors in cancer metastasis , 2018, Journal of Hematology & Oncology.

[27]  P. Galle,et al.  Improved Prediction of Survival by a Risk Factor-Integrating Inflammatory Score in Sorafenib-Treated Hepatocellular Carcinoma , 2018, Liver Cancer.

[28]  A. Singal,et al.  Stereotactic ablative radiotherapy for hepatocellular carcinoma: History, current status, and opportunities , 2018, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[29]  Qiong Yang,et al.  Clinical baseline and prognostic difference of platelet lymphocyte ratio (PLR) in right-sided and let-sided colon cancers , 2017, BMC Cancer.

[30]  W. Jochum,et al.  Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-to-Lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab. , 2017, Lung cancer.

[31]  K. E. Visser,et al.  Neutrophils in cancer: neutral no more , 2016, Nature Reviews Cancer.

[32]  Yao Liang,et al.  A novel and accurate predictor of survival for patients with hepatocellular carcinoma after surgical resection: the neutrophil to lymphocyte ratio (NLR) combined with the aspartate aminotransferase/platelet count ratio index (APRI) , 2016, BMC Cancer.

[33]  S. Shen,et al.  A novel and accurate predictor of survival for patients with hepatocellular carcinoma after surgical resection: the neutrophil to lymphocyte ratio (NLR) combined with the aspartate aminotransferase/platelet count ratio index (APRI) , 2016, BMC Cancer.

[34]  Y. Huang,et al.  A randomized trial of conventional fraction versus hypofraction radiotherapy for bone metastases from hepatocellular carcinoma , 2015, Journal of Cancer.

[35]  S. Clarke,et al.  Cancer-related inflammation and treatment effectiveness. , 2014, The Lancet. Oncology.

[36]  T. Fehm,et al.  Relationship between circulating tumor cells and peripheral T-cells in patients with primary breast cancer. , 2013, Anticancer Research.

[37]  G. Opdenakker,et al.  VEGF-A recruits a proangiogenic MMP-9-delivering neutrophil subset that induces angiogenesis in transplanted hypoxic tissue. , 2012, Blood.

[38]  T. Goto,et al.  Hepatocellular carcinoma with extrahepatic metastasis , 2011, Cancer.

[39]  Ping Yang,et al.  Clinical features and prognostic factors in patients with bone metastases from hepatocellular carcinoma receiving external beam radiotherapy , 2009, Cancer.

[40]  F. Schmidt Meta-Analysis , 2008 .

[41]  Sirong Chen,et al.  Dual-Tracer PET/CT Imaging in Evaluation of Metastatic Hepatocellular Carcinoma , 2007, Journal of Nuclear Medicine.

[42]  T. Kuzuya,et al.  Changes in the characteristics and survival rate of hepatocellular carcinoma from 1976 to 2000 , 2004, Cancer.

[43]  Qiang Zhao,et al.  Correlation of serum NLR, PLR and HALP with efficacy of neoadjuvant chemotherapy and prognosis of triple-negative breast cancer. , 2022, American journal of translational research.

[44]  N. Kemeny,et al.  Frequency, Morbidity, and Mortality of Bone Metastases in Advanced Hepatocellular Carcinoma. , 2018, Journal of the National Comprehensive Cancer Network : JNCCN.

[45]  P. Kupelian,et al.  Pretreatment Immune Parameters Predict for Overall Survival and Toxicity in Early-Stage Non-Small-Cell Lung Cancer Patients Treated With Stereotactic Body Radiation Therapy. , 2016, Clinical lung cancer.

[46]  Y. Maehara,et al.  Neutrophil-lymphocyte ratio reflects hepatocellular carcinoma recurrence after liver transplantation via inflammatory microenvironment. , 2013, Journal of hepatology.